A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of metastatic pancreatic ductaladenocarcinoma (PDAC).

• Evidence of homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAPloss detected in tumor tissue.

• Metastatic disease with at least 1 measurable lesion as per Response EvaluationCriteria in Solid Tumors version v1.1 (RECIST v1.1).

• Participants must not have received any systemic anticancer treatments in themetastatic setting.

• If clinically indicated and as per investigator discretion, participants may receiveup to 1 cycle of Nab-paclitaxel/Gemcitabine (nab-p/gem) in the metastatic settingand must have not progressed or required discontinuation due to intolerabletoxicity.

• Initial cycle of nab-p/gem administered in the metastatic setting must have beencompleted prior to randomization.

Exclusion Criteria:

• Concurrent malignancy (present during screening) requiring treatment or history ofprior malignancy active within 2 years prior to screening.

• Other protocol-defined Inclusion/Exclusion criteria apply.